Attached files
file | filename |
---|---|
8-K - FORM 8-K - JUNIPER PHARMACEUTICALS INC | y86056e8vk.htm |
EX-10.1 - EX-10.1 - JUNIPER PHARMACEUTICALS INC | y86056exv10w1.htm |
Exhibit 99.1
354 Eisenhower Parkway
Plaza I, Second Floor
Livingston, NJ 07039
Plaza I, Second Floor
Livingston, NJ 07039
TEL: (973) 994-3999
FAX: (973) 994-3001
FAX: (973) 994-3001
FOR IMMEDIATE RELEASE
COLUMBIA LABORATORIES REPURCHASES
3.3 MILLION SHARES OF COMMON STOCK
3.3 MILLION SHARES OF COMMON STOCK
LIVINGSTON, NJ August 10, 2010 Columbia Laboratories, Inc. (Nasdaq: CBRX)
has repurchased 3,333,330 shares of its Common Stock, par value $0.01 per
share, from investment funds for which Perry Corp. or an affiliate acts as
investment advisor and/or general partner at $0.90 per share for an aggregate
total purchase price of approximately $3 million. This transaction reduces the
total issued and outstanding shares of Common Stock by about 4% from
approximately 84.1 million to 80.8 million. This transaction also reduces the
Companys previously forecast 2010 year-end cash balance to approximately $20
million.
Our strong cash position after the close of the Watson Transactions, coupled
with our absence of debt, streamlined operations, and royalty and milestone
opportunities, enabled us to reduce outstanding shares at an advantageous
price, said Frank C. Condella, Jr., Columbias president and chief executive
officer. This share repurchase reflects our commitment to continue to create
value for our shareholders.
The shares were issued as part of the consideration for Columbias retirement
of its $40 million in convertible subordinated notes due on December 31, 2011.
The Benchmark Company, LLC, acted as an advisor on this transaction.
About Columbia Laboratories
Columbia Laboratories, Inc. is focused on developing products that utilize its
novel bioadhesive drug delivery technologies to optimize drug delivery in a
controlled, sustained manner. The Companys strategy is to fund new
development projects through proof of concept, then partner for later-stage
clinical development and commercialization. CRINONE® 8%
(progesterone gel) is marketed by Watson Pharmaceuticals in the United States
and by Merck Serono in foreign countries.
Columbia is conducting a randomized, double-blind, placebo controlled Phase
III clinical program, called the PREGNANT (PROCHIEVE® Extending
GestatioN A New Therapy) Study, to evaluate the safety and efficacy of
PROCHIEVE 8% (progesterone gel) to reduce the risk of preterm birth in women
with a cervical length between 1.0 and 2.0 centimeters as measured by
transvaginal ultrasound at mid-pregnancy. The primary endpoint of this study
is a reduction in the incidence of preterm birth at less than or equal to 32
weeks gestation vs. placebo. The Company expects study results before the end
of December 2010.
Columbias press releases and other company information are available online
at columbialabs.com.
Page 1 of 2
Columbia Laboratories Repurchases 3.3 Million Shares of Common Stock
August 10, 2010
August 10, 2010
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This
communication contains forward-looking statements, which statements are indicated by the words
may, will, plans, believes, expects, anticipates, potential, and similar expressions.
Such forward-looking statements involve known and unknown risks, uncertainties, and other factors
that may cause actual results to differ materially from those projected in the forward-looking
statements. Readers are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date on which they are made. Factors that might cause future results to
differ include, but are not limited to, the following: the successful marketing of CRINONE® by
Watson Pharmaceuticals, Inc., in the United States; the successful marketing of CRINONE by Merck
Serono outside the United States; the timely and successful completion of the ongoing Phase III
PREGNANT (PROCHIEVE® Extending Gestation A New Therapy) Study of PROCHIEVE 8% to reduce the risk of
preterm birth in women with a short cervix at mid-pregnancy; successful development of a
next-generation vaginal progesterone product; success in obtaining acceptance and approval of new
products and new indications for current products by the United States Food and Drug Administration
and international regulatory agencies; the impact of competitive products and pricing; the timely
and successful negotiation of partnerships or other transactions; the strength of the United States
dollar relative to international currencies, particularly the euro; competitive economic and
regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and
other risks and uncertainties that may be detailed, from time-to-time, in Columbias reports filed
with the SEC. Columbia does not undertake any responsibility to revise or update any
forward-looking statements contained herein.
CRINONE® and PROCHIEVE® are registered trademarks of Watson
Pharmaceuticals, Inc.
Contact |
||
Lawrence A. Gyenes
|
Seth Lewis | |
Senior Vice President, Chief Financial Officer & Treasurer
|
Vice President | |
Columbia Laboratories, Inc.
|
The Trout Group LLC | |
(973) 486-8860
|
(646) 378-2952 |
###
Page 2 of 2